^
    9ms
    KEYNOTE-D26: Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, Eikon Therapeutics | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • BDB018
    over1year
    Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1, Active, not recruiting, Eikon Therapeutics | Recruiting --> Active, not recruiting | N=50 --> 1 | Trial completion date: Dec 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • BDB018